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We identiﬁed the Wilms’ tumor protein, Wt1, as a novel transcriptional activator of the immuno-
suppressant cytokine interleukin-10 (IL-10). Silencing of Wt1 by RNA interference reduced IL-10
mRNA levels by approximately 90%. IL-10 transcripts were increased more than 15-fold upon forced
expression of Wt1. Electrophoretic mobility shift assay and chromatin immunoprecipitation
revealed a cis-element that was responsible for activation of the IL-10 promoter by Wt1 in murine
macrophages. Mutation of the Wt1 binding motif abrogated stimulation of the IL-10 promoter by
tumor necrosis factor-a (TNFa). These results suggest a novel immune regulatory function of Wt1
in controlling IL-10 gene expression.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Interleukin-10 (IL-10) is a class II a-helical cytokine which lim-
its the normal response to pathogenic stimuli by its potent im-
mune inhibitory function [1,2]. Changes in the expression of IL-
10 upon inﬂammatory stimuli and sympathetic activation are
mainly established on the transcriptional level, but the underlying
molecular mechanisms are not fully understood. It was reported
previously that lipopolysaccharide (LPS)-induced IL-10 transcrip-
tion may involve Sp1 activation by p38 mitogen-activated protein
kinase [3] or interaction of Stat3 with the 50-ﬂanking promoter re-
gion [4]. Furthermore, binding of CREB/ATF and C/EBP transcription
factors to cis-regulatory elements can mediate cAMP-dependent IL-
10 promoter activation in monocytes [5,6].
However, the cell-type speciﬁc, agonist-induced expression of
IL-10 may rely on the combined interaction of additional trans-fac-
tors with distinct consensus motifs in the IL-10 promoter. There-
fore, identiﬁcation of the relevant molecules and their respective
DNA recognition sites is necessary to gain a complete picture of
the transcriptional machinery that regulates IL-10. Based on the
presence of several predicted GC-rich binding elements within a
highly conserved promoter region, and previous reports relating
the Wilms’ tumor transcription factor Wt1 to enhanced cytokine
receptor expression [7], we reasoned that Wt1 might be a tran-
scriptional regulator of the IL-10 gene. Wt1 was initially describedchemical Societies. Published by E
on).as a tumor suppressor [reviewed in 8], but subsequent studies indi-
cated that it is also critical for the normal embryonic development
[8,9] and may even have oncogenic properties [10,11]. By demon-
strating that Wt1 indeed stimulates expression of the IL-10 gene,
we discovered a so far unrecognized immune regulatory function
of this protein.2. Materials and methods
2.1. Cell culture
Macrophagocytic RAW 264.7 cells (ATCC TIB-71) were obtained
from the American Type Culture Collection (ATCC). The M15 cell
line was established from mouse mesonephros with transgenic
expression of the large T protein of polyoma virus under the con-
trol of the early viral enhancer [12]. The UB27 and UD28 lines,
which contain the Wt1(KTS) and Wt1(+KTS) proteins, regulated
by a tetracycline-dependent promoter, were the gift of Dr. Chris-
toph Englert [13]. Wt1 protein expressed in both the UB27 and
the UD28 cell lines carries the exon 5 splice insertion [13]. Cells
were grown in Dulbecco’s Modiﬁed Eagle’s Medium (Invitrogen
GmbH, Karlsruhe, Germany) supplemented with 10% heat-inacti-
vated FCS (Biochrom KG, Berlin, Germany).
2.2. Cell transfections and reporter gene assays
RAW 264.7 cells were grown in six-well tissue culture plates to
approximately 20% conﬂuence. Transient transfections (Fugene6lsevier B.V. All rights reserved.
Table 1
Materials used for experimental procedures.
Cloning primers
mIL10prom-R1 GTCAAGCTTTCTTTTCTGCAAGGCTGCCT
mIL10prom-F5 ATTGAGCTCCATTATGACCTGGGAGTGCG
mIL10prom-F7 ATTGAGCTCCCTTTGCCAGGAAGGCC
mIL10mutA-F AGAAGAGTTAGTAGTAGCCTG
mIL10mutA-R CAGGCTACTACTAACTCTTCT
qPCR-primers
mGAPDH-F ACGACCCCTTCATTGACCTCA
mGAPDH-R TTTGGCTCCACCCTTCAAGTG
hActin-F AGAAAATCTGGCACCACACC
hActin-R GCCATCTCTTGCTCGAAGTC
hWT1-F AAGCTGTCCCACTTACAGATG
hWT1-R CAGCTGGAGTTTGGTCATGTT
mIL10-F ACTGCTATGCTGCCTGCTCTTACT
mIL10-R GAATTCAAATGCTCCTTGATTTCT
hIL10-F CCCAAGCTGAGAACCAAGA
hIL10-R CTTCATTGTCATGTAGGCTTC
ChIP-primers
mActinInt3-4-F1 ATAGGACTCCCTTCTATGAGC
mActinInt3-4-R1 TCCACTTAGACCTACTGTGCA
mIL10promBSChIP-F TGCAGAAGTTCATTCCGACCAG
mIL10promBSChIP-R GGCTTTGGTAGTGCAAGAGCAAG
EMSA-Oligos
mIL10EMSA-wt-F 50-TTAGAAGAGGGAGGAGGAGCCTGAAT-30-DIG
mIL10EMSA-wt-R 50-TTATTCAGGCTCCTCCTCCCTCTTCTAAAC-30
mIL10EMSA-mutA-F 50-GTTTAGAAGAGTTAGTAGTAGCCTGAATAA-30-
DIG
mIL10EMSA-mutA-R 50-TTATTCAGGCTACTACTAACTCTTCTAAAC-30
siRNAs
mWt1 siRNA ON-TARGETplus, SMARTpool siRNA against mouse
WT1, L-040686-01-0005, NM_144783
control siRNA siGENOME Non-targeting siRNA Pool #2
Antibodies
Rabbit IgG isotype
control
Cell Signaling, #3900S, 1 lg
Rabbit polyclonal
anti-WT1
Santa Cruz Biotechnology, sc-192, 1:500 or 1 lg
Rabbit polyclonal anti-
Sp1
Santa Cruz Biotechnology, sc-59, 1 lg
Rabbit monoclonal
anti-WT1
Abcam ab 52933
Rabbit polyclonal
anti-acetylated
histone 3
Upstate, #06-599, 1 lg
Mouse monoclonal
anti-pan-actin
Chemicon, MAB1501, 1:2000
Donkey polyclonal
anti-Rb-IgG-HRP
Santa Cruz Biotechnology, sc-2305, 1:15,000
Donkey polyclonal
anti-M-IgG-HRP
Santa Cruz Biotechnology, sc-2306, 1:20,000
Sheep polyclonal
anti-DIG-AP
Roche, #11093274910, 1:10,000
EMSA buffer
5 binding buffer 50 mM Tris–HCl pH 7.5, 250 mM KCl, 250 mM
NaCl, 5 mM MgCl2, 5 mM EDTA, 25 mM DTT,
25 mM PMSF
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with 400 ng of ﬁreﬂy luciferase constructs harbouring the murine
IL-10 promoter and 400 ng of Wt1 expression plasmids. A renilla
luciferase construct (200 ng per well) was co-transfected for the
normalization of transfection efﬁciencies. Luciferase activities
were measured in a luminometer (Microlite TLX1, MGM Instru-
ments, Hamden, CT) as described [14,15]. For pro-inﬂammatory
stimulation, transfected cells were incubated for 16 h with 10 ng/
ml TNFa (Sigma–Aldrich, Hamburg, Germany).
2.3. Transfection of siRNA
M15 cells were used at 60% conﬂuence in six-well culture plates
for simultaneous transfection (DharmaFECT 1 reagent, Thermo
Fisher Scientiﬁc, Bonn, Germany) with a pool of 4 different siRNAs
(50 pmoles per well) targeting the murine Wt1 gene (Dharmacon,
Thermo Fisher Scientiﬁc). siRNAs were speciﬁc for the murine Wt1
mRNA, did not target human transcripts, and were directed against
allWt1 splice variants. Pools of four non-targeting siRNAs (Dharm-
acon) with no homology to the vertebrate transcriptome were used
as a negative control. At 48 h following siRNA transfection, cells
were processed for mRNA and protein expression analysis.
2.4. Isolation of macrophages from human blood
To avoid activation of monocytes during the isolation proce-
dure, 40 ml whole blood was collected in EDTA tubes. Following
erythrocyte lysis (EL Buffer, Qiagen, Hilden, Germany), samples
were depleted of CD15+ eosinophils and neutrophils with magnetic
anti-CD15 microbeads (MACS, Miltenyi Biotec, Bergisch Gladbach,
Germany). Column eluates were co-stained with a FITC-coupled
mouse anti-human CD3 (clone UCTH1, #555332, Becton Dickin-
son) and a PE-coupled mouse anti-human CD14 antibody (cone
M5E2 #555398, Becton Dickinson), subjected to FACS-based cell
sorting for CD3+/CD14+ mononuclear cells (FACS Aria, Becton Dick-
inson), followed by a re-analysis. Total RNA was isolated using the
RNEasy Micro system (Qiagen) and subjected to reverse
transcription.
2.5. RNA puriﬁcation and reverse transcription (RT) real-time PCR
Total RNA was isolated from cultured cells with the Trizol re-
agent (Invitrogen). First-strand cDNA synthesis was followed by
real-time reverse transcription (RT) PCR (StepOnePlus, Applied Bio-
systems, Darmstadt, Germany) using SYBR Green PCR Master Mix
as described [16]. DNA sequences of the oligonucleotides used
for PCR ampliﬁcation are listed in Table 1. Relative transcript levels
were calculated by differences in Ct values according to the equa-
tion 2DDCt.
2.6. Plasmids
A DNA sequence extending from 349 base pairs (bp) to +1 bp
relative to the transcription start site in the murine IL-10 gene (Na-
tional Center for Biotechnology Information (NCBI) accession no.
NM_010548.1) was ampliﬁed by PCR and ligated into the HindIII-
SacI restriction sites of the pGL3basic reporter plasmid (Promega,
Mannheim, Germany). Likewise, site-directed mutations were gen-
erated by PCR [14,15]. All plasmids were subjected to DNA
sequencing (Euroﬁns MWG, Martinsried, Germany).
2.7. Chromatin immunoprecipitation (ChIP) assay
Approximately 106 cells (M15) were subjected to ChIP analysis
as described [16]. One microgram of the following control sera andantibodies were used: normal rabbit IgG (#3900S, Cell Signaling
Technology, Frankfurt, Germany), rabbit polyclonal anti-Wt1 (sc-
192, Lot #I0805, Santa Cruz, Biotechnology, Heidelberg, Germany),
rabbit monoclonal anti-Wt1 (ab52933, Abcam, Cambridge, UK),
rabbit polyclonal anti-Sp1 (sc-59, Santa Cruz, Biotechnology),
anti-acetylated histone 3 (#06-599, Upstate-Millipore, Darmstadt,
Germany). Antibody-bound proteins were precipitated for 1 h at
4 C with DNA-blocked protein G agarose (Millipore, Darmstadt,
Germany). DNA was ampliﬁed from puriﬁed immunoprecipitates
by quantitative PCR with oligonucleotides annealing within the
proximal promoter of the murine IL-10 gene containing the identi-
ﬁed Wt1 binding motif.
Fig. 2. IL-10 mRNA in M15 cells transfected either with pools of 4 different Wt1-
speciﬁc siRNAs or non-targeting siRNAs. IL-10 transcripts were determined by real-
time RT-PCR (A) (*P < 0.01, Student’s t-test, n = 5). Representative immunoblot for
the detection of Wt1 and pan-actin in siRNA transfected M15 cells (B).
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Non-radioactive EMSAs were performed with puriﬁed recombi-
nant GST-Wt1 protein [17] and recombinant human Sp1 (Promega,
Mannheim, Germany). A double-stranded, 30digoxigenin(DIG)-la-
beled (Euroﬁns MWG) oligonucleotide (50-AGAAGAGGGAGGA
GGAGCCTG-30) was selected on the basis of a predicted Wt1 bind-
ing site in the proximal promoter of the murine IL-10 gene. A sec-
ond 30DIG-labeled oligonucleotide contained a mutation in the
core Wt1 binding motif (underlined): 50-AGAAGAGTTAG-
TAGTAGCCTG-30. Competition experiments were performed with
an unlabeled oligonucleotide carrying the previously identiﬁed
Wt1 binding site of the vitamin D receptor (VDR) gene promoter
[17]. Binding reactions were performed for 30 min at room tem-
perature in 1x binding buffer (see Table 1) and separated on a
non-denaturing 6% polyacrylamide gel. DNA–protein complexes
were transferred onto positively charged nylon membrane,
blocked for 30 min at room temperature in blocking reagent solu-
tion (Roche), and subsequently incubated with an anti-DIG-AP
antibody (#11093274910, Roche, diluted 1:10.000). Oligonucleo-
tide–protein complexes were detected by NBT/BCIP staining
(Roche).
2.9. SDS–PAGE and immunoblotting
SDS–PAGE was performed with whole cell lysates as described
previously [18]. The following primary antibodies were used:
rabbit polyclonal anti-Wt1 (sc-192, Lot #I0805, Santa Cruz Bio-
technology, 1:500) and mouse monoclonal antibody against pan-
actin (#MAB1501, Chemicon-Millipore, Darmstadt, Germany,
1:2.000).
2.10. Animals
C57BL/6 mice with heterozygous Wt1 deletion (Wt1+/) were
originally obtained from Jackson Laboratories (Bar Harbor, ME,
USA) and mated in compliance with legal regulations. Embryos
were collected at the indicated time points (morning of vaginal
plug considered day E0.5) and genotyped by polymerase chain
reaction (PCR). Total RNA was prepared from isolated livers using
Trizol reagent, and reversely transcribed (1 lg/20 ll) using oli-
go(dT) primers and superscript II reverse transcriptase (Invitro-
gen). One twentieth of the reaction volume was used for PCR
quantiﬁcation.Fig. 1. IL-10 transcripts andWt1 protein in UB-27 (A) and UD-28 (B) cells with tetracyclin
measured after reverse transcription by real-time PCR (*P < 0.05, ANOVA with Bonferro
analysis using pan-actin as a loading control.2.11. Statistics
Paired Student’s t-tests and ANOVA with Bonferroni post-hoc
calculation were performed as indicated. P values <0.05 were con-
sidered statistically signiﬁcant.
3. Results
3.1. Cellular Wt1 and IL-10 mRNA levels are closely correlated
Initially, we analyzed the relation between cellular Wt1 and IL-
10 expression in osteosarcoma-derived UB27 and UD28 cell lines,
which contain the Wt1(KTS) and Wt1(+KTS) isoforms, respec-
tively, under the control of a tetracycline repressible promoter
[13]. Removal of tetracycline from the tissue culture medium re-
sulted in a time-dependent accumulation of Wt1(KTS) and
Wt1(+KTS) protein that was associated with a graded increase in
IL-10 transcripts (Fig. 1). In a complementary experimental ap-e-regulated expression of Wt1(KTS) andWt1(+KTS), respectively. IL-10mRNA was
ni correction as post-hoc test, n = 3). Wt1 protein was quantiﬁed by immunoblot
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contain robust amounts of Wt1 protein, for gene silencing by RNAi.
Remarkably, IL-10 mRNA levels were reduced by approximately
90% upon transfection of M15 cells with a pool of 4 different
Wt1-speciﬁc siRNAs vs. pooled non-targeting siRNA (Fig. 2).
3.2. Wt1 activates transcription from the IL-10 promoter
To study the molecular interaction of Wt1 protein with the IL-
10 gene, we co-transfected a ﬁreﬂy luciferase construct carrying
the murine IL-10 promoter together with Wt1 expression con-
structs into RAW 264.7 macrophages. This cell line, which does
not contain Wt1 protein at a sufﬁciently high level for detection
by immunoblot analysis (Fig. 6), has been proven useful in previous
investigations analyzing IL-10 gene regulation [19–21]. Normal-
ized luciferase activities revealed a more than ﬁve and eightfold
stimulation of the IL-10 promoter by the Wt1(KTS) and
Wt1(+KTS) proteins, respectively (*P < 0.01, n = 4, Fig. 3). The two
isoforms, which are generated by alternative mRNA splicing, differ
by the insertion of three amino acids (lysine-threonine-serine, KTS)Fig. 3. Regulation of the murine IL-10 promoter by theWt1(KTS) andWt1(+KTS) protein
activities. Asterisks indicate statistical signiﬁcance (*P < 0.01, ANOVA with Bonferroni co
(=1). Note, that mutation of a predicted consensus motif (Wt1 mut) abrogated activatio
Fig. 4. Electrophoretic mobility shift assay (EMSA) detecting recombinant Wt1(KTS)
promoter (Wt1?). Interaction could be competed with excess amounts of an unlabeled
receptor (VDR) gene promoter (lanes 1–6 in panel A) [17]. Mutation of the Wt1-consen
Addition of Sp1 to the binding reactions did not affect interaction of the IL-10 promoter e
and Sp1 proteins are indicated by arrows. ns marks a non-speciﬁc retardation band, whin the zinc ﬁnger domain of the Wt1 protein [22]. Site-directed
mutagenesis of a predicted Wt1-responsive element (MatInspector
software, Genomatix, Munich, Germany) abrogated IL-10 promoter
activation by the Wt1 proteins (Fig. 3).
3.3. Wt1 protein binds to a cis-element in the IL-10 promoter
Electrophoretic mobility shift assays (EMSA) revealed Wt1(KTS)
and Wt1(+KTS) binding to the identiﬁed cis-regulatory element in
the IL-10 promoter (Fig. 4). The speciﬁcity of DNA interaction is
indicated by the efﬁcient displacement of Wt1 protein with an
unlabeled Wt1-binding oligonucleotide (Fig. 4A). Since the Wt1-
responsive element in the IL-10 promoter overlaps with a previ-
ously identiﬁed Sp1 site [3,19], we examined whether Sp1 protein
could impair the binding afﬁnity for Wt1. Obviously, addition of
Sp1 protein to the binding reactions had no effect on the interac-
tion of the IL-10 promoter element with Wt1 protein (Fig. 4B). ChIP
analysis was performed to explore whether Wt1 protein binds to
the proximal IL-10 promoter also in a natural chromosomal conﬁg-
uration. We used M15 cells for these experiments, which – unlikes, respectively. Data are shown as relative light units normalized to renilla luciferase
rrection as post-hoc test, n = 4) vs. transfection with empty pCB6+ expression vector
n of the IL-10 promoter by the Wt1 proteins.
and Wt1(+KTS) proteins bound to the identiﬁed cis-element in the proximal IL-10
oligonucleotide carrying the previously identiﬁed Wt1 binding site of the vitamin D
sus motif abolished interaction with the Wt1 proteins (lanes 8 and 12 in panel A).
lement with Wt1 protein (panel B). Retardation bands caused by the binding of Wt1
ich is present in all lanes.
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quantities for immunoprecipitation. Approx. 2- and 2.5-fold
enrichments of amplicons from the IL-10 promoter were obtained
with two speciﬁc Wt1 antibodies vs. the use of normal rabbit ser-
um (Fig. 5). For comparison DNA was enriched less than twofold by
immunoprecipitation with antibody against Sp1 protein, which
had been reported earlier to trans-activate the IL-10 promoter [19].Fig. 5. Chromatin immunoprecipitation (ChIP) assay demonstrating interaction of Wt1 p
enrichment of DNA from the IL-10 promoter was obtained with two speciﬁc Wt1 antibodi
test, n = 4). Immunoprecipitations with antibodies against Sp1 [3,19] and acetylated h
untranslated region (UTR) of exon 1 of the murine IL-10 gene are depicted in panel B. The
for PCR ampliﬁcation of immunoprecipitated chromatin are underlined (B). +1 marks th
Fig. 6. Activation of the IL-10 promoter by TNFa in macrophages (A). RAW 264.7 cells
constructs, and subsequently incubated for 16 h with TNFa (10 ng/ml). Data are presented
of the identiﬁed Wt1-binding element in the proximal IL-10 promoter (Wt1 mut) abrog
test, n = 3). Treatment with TNFa (10 ng/ml) did not signiﬁcantly increaseWt1mRNA (B,
immunoblot analysis, respectively. For comparison, TNFa transcripts were signiﬁcantly
panel).3.4. A Wt1 binding site is required for tumor necrosis factor a (TNFa)-
induced activation of the IL-10 promoter
Next, we examined whether the identiﬁed Wt1-binding site is
necessary for IL-10 promoter activation by inﬂammatory stimuli.
RAW 264.7 macrophages transiently co-transfected with IL-10 pro-
moter reporter constructs and a renilla luciferase plasmid wererotein with the proximal IL-10 promoter in M15 cells (A). An approximately twofold
es compared to normal rabbit serum (A) (*P < 0.05, ANOVA with Bonferroni post-hoc
istone 3 were performed for control. The 50-ﬂanking sequence and part of the 50-
Wt1-responsive element is marked by the boxed area and the oligonucleotides used
e transcription start site in the IL-10 gene.
were co-transfected with a renilla luciferase plasmid and the indicated reporter
as relative light units normalized to renilla luciferase activities. Note, that mutation
ated stimulation by TNFa (*P < 0.05, ANOVA with Bonferroni correction as post-hoc
left panel) and protein (C) in RAW 264.7 cells as quantiﬁed by real-time RT-PCR and
elevated (*P < 0.01, Student’s t-test, n = 3) in response to TNFa treatment (B, right
Fig. 7. IL-10mRNA in the livers of wild-type (Wt1+/+) murine embryos (E12.5) and theirWt1-deﬁcient (Wt1/) littermates (A). Statistical signiﬁcance is indicated by asterisks
(P < 0.05; Student’s t-test, n = 3). (B) Wt1 and IL-10 mRNA in mature CD3+/CD14+ monocytes (Mo1, Mo2) isolated freshly from human blood samples (see Section 2) and in
U2OS osteosarcoma cells.
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transcription from the IL-10 promoter. Strikingly, promoter activa-
tion by TNFa was abrogated upon mutation of the identiﬁed Wt1-
sensitive element (Fig. 6A). Treatment with TNFa did not increase
Wt1 mRNA and protein in RAW 264.7 cells (Fig. 6B, left panel, C),
but strongly enhanced TNFa transcripts (Fig. 6B, right panel).
3.5. Wt1 deﬁciency reduces IL-10 gene expression in the fetal liver
To assess whether Wt1 is necessary for normal IL-10 gene
expression in vivo, we quantiﬁed IL-10 transcripts in the livers of
wild-type murine embryos (E12.5) and their Wt1-deﬁcient
(Wt1/) littermates. IL-10 mRNA levels were signiﬁcantly lower
(P < 0.05; Student’s t-test) in Wt1/ than in wild-type fetal livers
(Fig. 7A). Interestingly, Wt1 and IL-10 transcripts could also be de-
tected in mature monocytes that were freshly isolated from human
blood (Fig. 7B).
4. Discussion
In this study we identiﬁed IL-10 as a novel putative downstream
target gene of the Wilms’ tumor protein Wt1. Activation of the IL-
10 gene by Wt1, which are co-expressed in mature monocytic cells
(Fig. 7B), is indicated by the following observations: Cellular Wt1
and IL-10 levels were closely correlated (Figs. 1 and 2) and Wt1
protein enhanced transcription from the IL-10 promoter through
interaction with a GC-rich consensus motif (Figs. 3–5). Since Sp1,
which binds to an overlapping sequence in the IL-10 promoter
[3,19], failed to displace Wt1 protein from the identiﬁed cis-ele-
ment, a robust interaction may be assumed (Fig. 4). Our results ex-
tend those by Tone et al. who speculated on a role for Wt1 in the
regulation of IL-10 expression, however, without being able to
demonstrate binding of Wt1 to the IL-10 promoter [23]. Further
on, the identiﬁed Wt1-responsive element was necessary for stim-
ulation of the IL-10 promoter by TNFa (Fig. 6) suggesting that Wt1
confers IL-10 promoter responsiveness to pro-inﬂammatory sig-
nals. The assumption that IL-10 is a novel bona ﬁde target gene of
Wt1 is supported by our results that IL-10 transcripts were signif-
icantly reduced in the livers of Wt1-null embryos compared to
their wild-type littermates (Fig. 7A).
Downstream signaling of the TNF receptor I (TNFRI) involves
activation of the transcription factors NF-jB and AP-1 [24]. Inter-
estingly, two conserved NF-jB binding elements were previously
identiﬁed in the promoter of theWt1 gene, whose activity was sig-
niﬁcantly enhanced by NF-jB in transient transfection experi-
ments [25]. Even though we and others did not observe
increased Wt1 expression in response to pro-inﬂammatory cyto-
kines [Fig. 6B and 26], it is conceivable that NF-jB and other intra-cellular signal transducers of TNFRI facilitate the binding of Wt1
protein to its GC-rich consensus site in the IL-10 promoter.
Another interesting aspect of this study is our observation that
the Wt1(+KTS) protein was even more efﬁcient in stimulating the
IL-10 promoter than the Wt1(KTS) isoform. Likewise, Wt1(+KTS)
was previously found to bind to cis-regulatory elements in the
genes encoding vitamin D receptor (VDR) and nephrin, and
strongly trans-activated their respective promoters [17,27]. The
two Wt1 proteins differ with regard to the presence/absence of
three amino acids (lysine, threonine, serine, KTS) in the C-terminal
zinc ﬁnger domain due to alternative mRNA splicing [22]. Wt1
isoforms with the KTS splice insertion are generally believed to ex-
hibit increased RNA binding afﬁnity and play a possible role in
post-transcriptional gene regulation [12]. Notably, a most recent
genome-wide immunoprecipitation analysis revealed strong inter-
action of the predominant Wt1(+KTS) form with the promoter of
the planar cell polarity gene Scribble (SCRB) in podocytes of the
kidney [28]. The latter study along with our own previous and
present observations [Figs. 3 and 4, 17 and 27] extends the role
of the Wt1(+KTS) molecule towards a DNA binding protein which
is also involved in promoter regulation. It is difﬁcult to directly
compare the potency of Wt1(KTS) and Wt1(+KTS) proteins in
stimulating endogenous IL-10 expression, because Wt1(KTS) pro-
tein in UB27 cells increased to a higher level than Wt1(+KTS) in
UD28 cells upon induction (Fig. 1).
Activation of the IL-10 gene by Wt1 could become important in
different contexts.
High levels of the full-length, wild-type Wt1 protein are fre-
quently found in human leukemias and solid tumors [29], which
arise from tissues that normally do not express WT1, suggesting
that WT1, initially identiﬁed as a tumor suppressor [8], may exhi-
bit oncogenic properties [10,11]. How Wt1 fulﬁls its dual role as a
tumor suppressor and putative oncogene is largely unknown. It is
conceivable that a cell type-dependent regulation of variable target
genes contributes to the multiple functions of Wt1 [30]. Notably,
IL-10 can be produced by malignant cells, and inﬁltrating macro-
phages and lymphocytes in various malignancies [31,32]. The
immunosuppressant effect of IL-10 likely permits malignant cells
to escape from immune surveillance, thereby promoting tumor
growth [33–35]. One can therefore speculate whether enhanced
IL-10 expression in response to Wt1 represents a pro-oncogenic
switch in certain tumors.
Our previous studies revealed a crucial role for Wt1 in blood
vessel formation in the heart. Thus,Wt1-deﬁcient murine embryos
exhibited a failure of normal vascularisation of their hearts [36],
and Wt1 was expressed de novo in myocardial blood vessels of rats
after infarction [37]. Remarkably, IL-10 was also up-regulated in
the hearts of mice following coronary artery ligation [38], and IL-
L.K. Sciesielski et al. / FEBS Letters 584 (2010) 4665–4671 467110 treatment signiﬁcantly improved left ventricular function and
post-infarct remodelling [39]. This raises the intriguing possibility
that Wt1 and IL-10 act synergistically in generating a microenvi-
ronment that enables the formation of new blood vessels in the in-
jured heart. It will be a major challenge for future studies to
decipher the molecular pathways involved herein.
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